Pretorius T, van Rensburg G, Dyer R A, Biccard B M
Department of Anaesthesia and Perioperative Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Department of Anaesthesia and Perioperative Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Int J Obstet Anesth. 2018 May;34:85-95. doi: 10.1016/j.ijoa.2017.12.004. Epub 2017 Dec 20.
The optimal fluid management strategy to ensure best outcomes in preeclamptic patients remains a controversial issue, with little evidence to support any one approach.
The aim of this systematic review was to investigate the effect of various fluid management strategies on clinical outcomes, haemodynamic indices and biochemical markers in preeclamptic women and their babies. Primary outcome measures were the occurrence of pulmonary oedema and/or the development of renal impairment.
A systematic review of randomised fluid management strategies was conducted. Five electronic databases were searched using the expanded search terms: 'intravenous fluid', 'plasma substitutes', 'intravenous fluid management', 'intravenous fluid therapy', plasma volume expansion', 'fluid restriction', 'oncotic therapy', 'crystalloids', 'colloids', 'preeclampsia', 'toxemia of pregnancy', 'pregnancy-induced hypertension', 'eclampsia' and 'gestational proteinuric hypertension'.
Six randomised controlled trials (RCTs), from nine publications, were included in the final analysis. There were no differences between groups with respect to the incidence of pulmonary oedema, perinatal mortality, preterm delivery and caesarean section. Colloid volume expansion was associated with a significantly lower systolic and diastolic blood pressure, but had no effect on heart rate or cardiac index. Data on systemic vascular resistance (SVR), serum atrial natriuretic peptide (ANP) and urine volume could not be aggregated.
Data on the ideal fluid strategy in women with preeclampsia is limited, and insufficient to make any strong recommendations. Further randomised controlled studies are needed to provide more evidence for which fluid management strategies are best suited to this heterogeneous patient group.
确保子痫前期患者获得最佳治疗效果的最佳液体管理策略仍是一个有争议的问题,几乎没有证据支持任何一种方法。
本系统评价的目的是研究各种液体管理策略对子痫前期妇女及其婴儿的临床结局、血流动力学指标和生化标志物的影响。主要结局指标是肺水肿的发生和/或肾功能损害的发展。
对随机液体管理策略进行系统评价。使用扩展搜索词检索了五个电子数据库:“静脉输液”、“血浆代用品”、“静脉液体管理”、“静脉液体治疗”、“血浆容量扩充”、“液体限制”、“胶体渗透压治疗”、“晶体液”、“胶体液”、“子痫前期”、“妊娠中毒症”、“妊娠高血压综合征”、“子痫”和“妊娠蛋白尿性高血压”。
最终分析纳入了来自九篇出版物的六项随机对照试验(RCT)。各组在肺水肿发生率、围产期死亡率、早产和剖宫产方面无差异。胶体液扩容与收缩压和舒张压显著降低相关,但对心率或心脏指数无影响。关于全身血管阻力(SVR)、血清心钠素(ANP)和尿量的数据无法汇总。
关于子痫前期妇女理想液体策略的数据有限,不足以提出任何有力建议。需要进一步的随机对照研究,以提供更多证据,证明哪种液体管理策略最适合这一异质性患者群体。